128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity
Abstract
Tirzepatide (TZP) promotes significant and clinically meaningful weight loss. In a randomized blinded clinical trial in people with obesity undergoing caloric restriction, we investigated the effect of TZP vs Placebo (PBO) on food intake during ad libitum lunch and dinner, appetite, food preference and craving. In this 18wk phase 1 study, 55 people with obesity, with baseline body weight of 102.8 kg were randomized (1:1) to TZP 15 mg or PBO. Food intake was measured during ad libitum lunch (664 kcal, PBO and 682 kcal, TZP) and dinner (1178 kcal, PBO and 1190 kcal, TZP) at baseline and after 18wk of treatment. We measured appetite during fasting and standardized mixed meal tolerance test (sMMTT) with visual analogue scale (VAS) and retrospective VAS (average ratings over the previous week). Food cravings and preferences were measured with the Food Craving Inventory (FCI) and Food Preference Questionnaire (FPQ) at baseline, 8wk and 18wk. At 18wk, mean body weight loss was 16.7 kg with TZP and 8.3 kg with PBO (p<0.001). TZP significantly decreased food intake from baseline during lunch (-285±42 kcal) and dinner (-631±58 kcal) compared to PBO (60± 42, and -116±58 kcal, respectively). TZP significantly lowered appetite at fasting and at each time point during the sMMTT, resulting in decreased hunger and prospective food consumption and increased fullness. Based on retrospective VAS, appetite changes started at 1wk. TZP significantly decreased food preference scores in 10 of 12 FPQ metrics at 8wk and 18wk compared to PBO. TZP significantly decreased the overall FCI score and the sweets, carbohydrates and starches, and fast-food fats sub scores, but not the high fat and fruit and vegetable sub scores, at 8wk and 18wk, compared to PBO. In conclusion, TZP decreased food intake, appetite and food craving and preference. TZP appears to reduce body weight via reductions in food intake and the drive to eat. Disclosure: C.K.Martin: Board Member; EHE Health, Wondr Health, Other Relationship; ABGIL, Research Support; Pack Health, Evidation Health, Lilly, WW International, Inc. T.Coskun: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. E.Ravussin: Advisory Panel; Novartis, Research Support; Eli Lilly and Company, Novartis AG. G.Sanchez-delgado: Research Support; Eli Lilly and Company, Novo Nordisk, Abbott, Maastricht instruments, Vyaire Medical, ParvoMedics, Cosmed, Speaker's Bureau; Eli Lilly and Company. H.Nishiyama: None. J.Li: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. S.Urva: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. E.J.Pratt: Employee; Eli Lilly and Company. Z.Milicevic: Employee; Eli Lilly and Company. A.Haupt: Employee; Lilly, Stock/Shareholder; Lilly. Funding: Eli Lilly and Company
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies of ad libitum food intake during a buffet-style lunch have identified up to approximately 345-kcal greater reductions from baseline in mean energy intake in participants receiving AOMs compared with placebo.
“Studies of ad libitum food intake during a buffet-style lunch have identified up to approximately 345-kcal greater reductions from baseline in mean energy intake in participants receiving AOMs compared with placebo [21,30,31].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [31]
Medical nutrition therapy delivered by registered dietitians has been associated with improvements in dietary quality, health outcomes, and weight-loss outcomes.
“Medical nutrition therapy delivered by registered dietitians has been associated with improvements in dietary quality, health outcomes, and weight-loss outcomes [35,36].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [35]
Cites
Still being checked.
Cited by
Sorted by citations
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154 · see citing works
“Different studies suggest reduced cravings for savory foods and high-fat foods [141,142]; sweet, savory, or dairy foods [135]; salty, spicy, starchy, or dairy foods [138]; and sweets, carbohydrates, starches, and fast-food fats [145].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143 · see citing works
Nutritional considerations with antiobesity medications
Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., Jouravskaya, I., et al. (2024) · Obesity · doi:10.1002/oby.24067 · Cited by 134 · see citing works
“Studies of ad libitum food intake during a buffet-style lunch have identified up to approximately 345-kcal greater reductions from baseline in mean energy intake in participants receiving AOMs compared with placebo [21, 30, 31].”
Martin, C. K., Carmichael, O. T., Carnell, S., Considine, R. V., Kareken, D. A., Dydak, U., Mattes, R. D., Scott, D., Shcherbinin, S., Nishiyama, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03774-9 · Cited by 74 · see citing works
Self-citationPsaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 44 · see citing works
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42 · see citing works
Sievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 32 · see citing works
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28 · see citing works
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 26 · see citing works
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence
Sattar, N. A., García‐Pérez, L., Rodríguez, Á., Kapoor, R., Stefański, A., & Hankosky, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16549 · Cited by 22 · see citing works
GLP-1 Receptor Agonists – Good for Body Weight, Bad for Micronutrient Status?
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107587 · Cited by 18 · see citing works
Kakoschke, N., Henry, B. A., Cowley, M. A., & Lee, K. (2024) · Nutrients · doi:10.3390/nu16193238 · Cited by 12 · see citing works
Jebeile, H., Danielsen, Y. S., Sumithran, P., Lorien, S. J., Jardine, I. R., Baur, L. A., & Lister, N. B. (2025) · Obesity Reviews · doi:10.1111/obr.70049 · Cited by 10 · see citing works
Czernichow, S., Rassy, N., Carette, C., Shoung, N., Hu, F. B., & Rives‐Lange, C. (2025) · Obesity Reviews · doi:10.1111/obr.13890 · Cited by 10 · see citing works
Guo, L., Dong, X., Ma, J., Liu, M., Lu, Y., Wang, H., Li, Q., Li, L., Deng, Y., & Xu, J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00248-7 · Cited by 8 · see citing works
Kushner, R. F., Johansen, O. E., Araujo Torres, K., Phan, T.-M., & Marczewska, A. (2025) · Obesities · doi:10.3390/obesities5020029 · Cited by 5 · see citing works
Li, X., Cao, D., Sapin, H., Wang, F., Hunter, T. M., RAIBULET, N. K., Denning, M., & Kaplan, L. M. (2025) · Obesity · doi:10.1002/oby.70067 · Cited by 3 · see citing works
GLP-1/GIP Receptor Agonists: Mechanism of Action of Tirzepatide
Oh, T. J. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.76 · Cited by 2 · see citing works
Quarles, W. R., Brown, A., & Binks, M. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01925-z · Cited by 1 · see citing works
TIRZEPATIDA: A MAIS NOVA ESPERANÇA NA PERDA DE PESO
Filho, P. D. O. F., Pinto, M. S. L., de Castro, L. D. S., Amorim, Y. C., Zamengo, F. D. O. G., Motta, M. B., & Lima, R. F. D. S. (2025) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v11i11.22190
Einfluss von GLP-1-Analoga auf die Mikronährstoffversorgung
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Ernährung & Medizin · doi:10.1055/a-2492-9615
Hunter, T. M., Makin, H., Gerber, C., Bottomley, C., He, X., Pisani, S., Shepherd, M., Collins, E., Golden, A. K., & Bays, H. E. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100288
- Authors
- MARTIN, C. K., RAVUSSIN, E., SANCHEZ-DELGADO, G., NISHIYAMA, H., LI, J., URVA, S., PRATT, E. J., MILICEVIC, Z., HAUPT, A., & COSKUN, T.
- Affiliations
- Baton Rouge, LA, Indianapolis, IN
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2023-06-20
- Volume
- 72
- Issue
- Supplement_1
- ISSN
- 0012-1797 (ISSN-L)
- OpenAlex
- W4381378266
- Cited by
- 21
- References
- 0
- Citations by year
- 2026: 1 · 2025: 15 · 2024: 5
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, obesity, weight loss, dietary intake, appetite, food preferences, food cravings, caloric restriction, GLP-1 receptor agonists, mixed meal tolerance test, satiety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
